Document:

Exhibit
10.1

 

SABBATICAL
AGREEMENT

 

This
SABBATICAL AGREEMENT (this “Agreement”) is made and entered into as of the 22nd day of September, 2021
(the “Effective Date”) by and between VIVOS THERAPEUTICS, INC., a Delaware corporation having its principal
place of business at 9137 S. Ridgeline Blvd., Suite 135, Highlands Ranch, Colorado 80129 (the “Company”) and DR.
G. DAVE SINGH, an individual currently residing in Sandia Park, New Mexico (the “Executive”). As used herein,
the term “Parties” shall be used to refer to the Company and Executive jointly.

 

RECITALS

 

WHEREAS,
on October 9, 2020, the Executive executed an Amended and Restated Employment Agreement with the Company to become its Chief Medical
Officer (the “Amended Employment Agreement”);

 

WHEREAS,
on July 8, 2021, Dr. Singh requested a sabbatical from his role as Chief Medical Officer of the Company as he was awarded an Adjunct
Professor position with Stanford University;

 

WHEREAS,
the Company believes that its executives from time-to-time may benefit from a sabbatical to focus on research, continuing education,
or other special projects without having to perform their regularly assigned job duties and responsibilities;

 

WHEREAS,
the Parties desire to amend the Amended Employment Agreement, by virtue of this Agreement; and

 

WHEREAS,
the Parties desire to amend Executive’s relationship as a member of the Board of Directors of the Company.

 

NOW
THEREFORE, in consideration of the promises and covenants contained herein, the Company is willing to grant Executive’s sabbatical
request pursuant to the following terms:

 

	 	1.	Term.
    The term of this Agreement will be twelve (12) months from the date of the commencement of the sabbatical, which will begin on September
    1, 2021.
	 	 	 
	 	2.	Compensation
    and Benefits. During the sabbatical, Executive’s compensation and benefits shall remain the same as set forth in the Amended
    Employment Agreement.
	 	 	 
	 	3.	Amendment
    of Termination by Executive for Good Reason. Pursuant to Executive’s request to undertake the sabbatical, this Agreement
    amends Section 3(d)(i) of the Amended Employment Agreement by modifying the following subsection as follows: 

 

.
.. . (i) except in connection with a sabbatical of Executive upon terms mutually agreed by the Company and Executive, the assignment to
Executive of duties inconsistent with the position and nature of Executive’s employment as Chief Medical Officer, the substantial
and material reduction of the duties of Executive, which is inconsistent with the position and nature of Executive’s employment
.. . .

 

    	1

     

    

 

	 	4.	Amendment
    of Executive’s Essential Duties and Responsibilities. During the sabbatical, Executive’s Essential Duties and Responsibilities
    under Attachment A to the Amended Employment Agreement shall be suspended. Executive while on sabbatical will not exercise any of
    the duties or responsibilities contained in Attachment A to the Amended Employment Agreement. However, Executive and Company have
    mutually agreed that during Executive’s sabbatical, Executive will perform the Job Duties and responsibilities contained in
    Attachment 1 to this Agreement. Section 6 of this Agreement sets forth the conditions for determining if Executive’s Essential
    Duties and Reinstatement will be reinstated. The provisions of Section 4 of the Amended Employment Agreement, which incorporated
    by reference Addendum D to the Executive’s Employment Agreement dated May 6, 2017, are hereby reaffirmed to apply to during
    the term of Executive’s sabbatical; provided that for the sake of clarification, the phrase “developed entirely
    on my own time” in Section 1 of such Addendum D shall be construed to include time spent by Executive during the sabbatical
    outside of Executive performing the Job Duties and Responsibilities on Attachment 1 during the sabbatical, including without limitation
    with respect to surgical innovations and related approaches that are not competitive with the Company and further outside of any
    obligations Executive may have to Stanford University or any other educational institution.
	 	 	 
	 	5.	Executive’s
    Job Duties and Responsibilities During Sabbatical. Executive’s Job Duties and Responsibilities during the sabbatical are
    set forth in Attachment 1 to this Agreement, incorporated herein and integrated herewith by this reference. 
	 	 	 
	 	6.	Reinstatement
    of Executive’s Essential Duties and Responsibilities. Approximately thirty (30) days prior to the expiration of this Agreement,
    the Company’s Board of Directors will determine after receiving any discussion or request from Executive, whether to reinstate
    Executive’s Essential Duties and Responsibilities contained in Attachment A to the Amended Employment Agreement. However, the
    Company’s Board of Directors shall have the sole discretion to determine whether Executive’s Essential Duties and Responsibilities
    will be fully reinstated or modified. Notice of the Company’s reinstatement determination will be provided to Executive in
    accordance with Section 12 of the Amended Employment Agreement. Subject to Section 7, below, the Company’s determination not
    to reinstate Executive’s Essential Duties and Responsibilities contained in Attachment A to the Amended Employment Agreement
    shall constitute “Good Reason” under Section 4(d)(i) of the Amended Employment Agreement.
	 	 	 
	 	7.	Extension
    of Sabbatical. In lieu of reinstatement, the Company’s Board of Directors, upon Executive’s request, may extend this
    Agreement for consecutive 12-month periods upon request from the Executive at the Board of Directors discretion. Notice of any extension
    determination will be provided to Executive in accordance with Section 12 of the Amended Employment Agreement. As long as any payments
    are being made by Company to Executive at any time, as required under this Agreement and under the Amended Employment Agreement between
    the Company and Executive, including any severance payments following termination for any reason, Executive will continue to perform
    the responsibilities contained bullet point three on Attachment 1 at the request of the Company.
	 	 	 
	 	8.	No
    other Amendments or Modifications to the Amended Employment Agreement. Except as otherwise modified by this Sabbatical Agreement,
    the remaining terms and conditions of the Executive’s Amended Employment Agreement remain the same and remain in full force
    and effect. Executive represents and warrants that Executive’s entry into and performance of this Agreement does not conflict
    with any other agreements of Executive, including, without limitation, Executive’s agreement with Stanford University or any
    other educational institution.
	 	 	 
	 	9.	Resignation
    from Board of Directors. On or before date of the commencement of the sabbatical, which will begin on September 22, 2021, Executive
    shall also resign his position from the Company’s Board of Directors as of September 22, 2021. The Nominating Governance Committee
    shall have the sole discretion to consider a subsequent appointment to the Board of Directors at a future date; provided that upon
    reinstatement under Section 6, above, Executive will become eligible for nomination to the Company’s Board of Directors and
    such nomination shall not be unreasonably withheld.

 

[Intentionally
Blank; Signature Page to Follow]

 

    	2

     

    

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Sabbatical Agreement as of the day of the date first written above.

 

	 	VIVOS
    THERAPEUTICS, INC.
	 	 	 
	 	By:	/s/
                                            R. Kirk Huntsman

	 	Name:	R.
    Kirk Huntsman
	 	Title:	CEO
	 	 	 
	 	EXECUTIVE:
	 	 
	 	/s/
G. Dave Singh

	 	Name: 	DR.
                                            G. DAVE SINGH

	 	Title:	Founder
    and Chief Medical Officer

 

    	3

     

    

 

ATTACHMENT
1

 

EXECUTIVE’S
JOB DUTIES AND RESPONSIBILITIES WHILE ON SABBATICAL 

 

Executive’s
Job Duties and Responsibilities while on Sabbatical shall include the following.

 

	 	●	Research:
    Advise Company regulatory personnel and consultants concerning clinical studies, on an as-needed basis.
	 	 	 
	 	●	Device
    Development: Collaborate with applicable Company personnel and consultants to develop, test and create a prototype for the next generational
    devices, using mutually agreed upon resources, equipment and delivery of design history files with funding provided by the Company.
	 	 	 
	 	●	Attend
    and/or make presentations at national, regional, local, and international assemblies and conferences as a Company representative
    that is consistent with the Company’s messaging concerning ongoing research and development of new technologies and products.
    
	 	 	 
	 	●	Executive
    shall be eligible for earning incentive compensation on the achievement of open MBO milestones and performance objectives established
    on Attachment B of his Amended Employment Agreement.

 

    	4Exhibit 4.1

 

		SPECIMEN UNIT CERTIFICATE	NUMBER UNITS [FATPU]-                 
	SEE REVERSE FOR CERTAIN DEFINITIONS	FAT PROJECTS ACQUISITION CORP	 
	 	 	 
	 	 	CUSIP [*]

 

UNITS CONSISTING OF ONE CLASS
A ORDINARY SHARE AND ONE-HALF OF ONE WARRANT

 

THIS CERTIFIES THAT ______________________________________________________________________________________________

 

is the owner of _______________________________________________________________________________________________________
Units.

 

Each Unit (“Unit”) consists of one
Class A ordinary share, with a par or nominal value of US $0.0001 per share (“Ordinary Shares”), of Fat Projects Acquisition
Corp, a Cayman Islands exempted company (the “Company”), and one redeemable warrant (each, a “Warrant”). Each
redeemable Warrant entitles the holder thereof to purchase one Ordinary Share at a price of $11.50 per full share (subject to adjustment),
upon the later to occur of (i) the Company’s completion of a merger, share exchange, asset acquisition, share purchase, recapitalization,
reorganization or other similar business combination with one or more businesses or entities (each, a “Business Combination”)
or (ii) one year from the closing of the Company’s initial public offering. The Ordinary Shares and Warrants comprising the Units
represented by this certificate are not transferable separately prior to the fifty-second (52nd) day after the date of the prospectus
relating to the Company’s initial public offering, unless EF Hutton, division of Benchmark Investments,
LLC  (“Hutton”) determines that an earlier date is acceptable, but in no event will the Ordinary Shares and Warrants
be traded separately until the Company files with the Securities and Exchange Commission (the “SEC”) a current report on Form
8-K which includes an audited balance sheet reflecting the receipt by the Company of the gross proceeds from its initial public offering
including the proceeds received by the Company from the exercise of the over-allotment option thereto, if the over-allotment option is
exercised. If the over-allotment option is exercised after the date of the prospectus, we will file an amendment to the Form 8-K or a
new Form 8-K to provide updated financial information to reflect the exercise of the over-allotment option. We will also include in the
Form 8-K, or amendment thereto, or in a subsequent Form 8-K, information indicating if the underwriters has allowed separate trading of
the Ordinary Shares and Warrants prior to the 52nd day after the date of the prospectus.

 

The terms of the Warrants are governed by a
Warrant Agreement, dated as of , 2021, between the Company and Continental Stock Transfer & Trust Company, as Warrant Agent, and are
subject to the terms and provisions contained therein, all of which terms and provisions the holder of this certificate consents to by
acceptance hereof. Copies of the Warrant Agreement are on file at the office of Continental Stock Transfer & Trust Company at 1 State
Street, 30th Floor, New York, New York 10004, and are available to any Warrant holder on written request and without cost.

 

This certificate is not valid unless countersigned
by the Transfer Agent and Registrar of the Company.

 

 

This certificate shall be governed and construed
in accordance with the internal laws of the State of New York, without regard to conflicts of laws principles thereof.

 

Witness the facsimile signature of its duly
authorized officers.

 

	By	 
	 	 	 
	 	President	 

 

     

     

    

 

Fat Projects Acquisition Corp

 

The Company will furnish without
charge to each unitholder who so requests, a statement of the powers, designations, preferences and relative, participating, optional
or other special rights of each class of shares or series thereof of the Company and the qualifications, limitations, or restrictions
of such preferences and/or rights.

 

The following abbreviations,
when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to
applicable laws or regulations:

 

	 	TEN
    COM –	as
    tenants in common	UNIF
    GIFT MIN
	 	 	 	ACT
    - _____ Custodian ______
	 	TEN
    ENT –	as
    tenants by the entireties	 	(Cust)               
(Minor)
	 	JT
    TEN –	as
    joint tenants with right of survivorship	 	under Uniform Gifts to Minors
	 	 	and
    not as tenants in common	 	Act ______________
	 		 	 	(State)

 

Additional Abbreviations may also be used though
not in the above list.

 

For value received, ___________________________
hereby sell(s), assign(s) and transfer(s) unto

 

PLEASE INSERT SOCIAL SECURITY OR OTHER

IDENTIFYING NUMBER OF ASSIGNEE(S)

 

 

(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING
ZIP CODE, OF ASSIGNEE(S))

 

 

 

 

	 	Units

 

represented by the within Certificate, and
does hereby irrevocably constitute and appoint

 

	 	Attorney

to
transfer the said Units on the books of the within named Company will full power of substitution in the premises.

 

Dated                         

 

 

		Notice:	The signature to this assignment must correspond with the name as written
upon the face of the certificate in every particular, without alteration or enlargement or any change whatever.

 

Signature(s) Guaranteed:

 

 

 

THE SIGNATURE(S) SHOULD BE GUARANTEED
BY AN ELIGIBLE GUARANTOR INSTITUTION

(BANKS, STOCKBROKERS, SAVINGS AND LOAN
ASSOCIATIONS AND CREDIT UNIONS WITH

MEMBERSHIP IN AN APPROVED SIGNATURE
GUARANTEE MEDALLION PROGRAM,

PURSUANT TO S.E.C. RULE 17Ad-15).

 

The holder of this certificate shall be entitled to receive funds with
respect to the underlying ordinary share from the trust fund only in the event of the Company’s liquidation upon failure to consummate
a business combination or if the holder seeks to convert his or her respective share underlying the unit upon consummation of such business
combination or in connection with certain amendments to the Company’s amended and restated memorandum and articles of association.
In no other circumstances shall the holder have any right or interest of any kind in or to the trust fund.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]